The Institut Pasteur has uncovered a previously unknown mechanism of action for a drug called lenacapavir. This antiretroviral is used for people living with HIV or for prevention, and is administered only twice a year. This treatment does more than simply block the virus from entering the cell: it acts directly within the nucleus, redirecting HIV to areas of the DNA where it can no longer replicate effectively. This discovery helps explain the remarkable long-term efficacy of this compound.

Find out more